Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
110Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2020 | $0.00 | $-126.35M | $-3.85 |
| 2019 | $0.00 | $-111.83M | $-4.05 |
| 2018 | $0.00 | $-88.96M | $-3.64 |
| 2017 | $0.00 | $-32.74M | $-1.28 |
| 2016 | $0.00 | $-3.08M | $-0.11 |
Social Signal Score
Earnings
Typical surprise -1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 27$-0.58 vs $-0.33miss
- Fri, May 14$-0.90 vs $-0.85miss
- Tue, Feb 23$-0.87 vs $-0.77miss
- Wed, Oct 28$-0.93 vs $-1.19beat
- Thu, Jul 30$-1.09 vs $-1.07miss
- Tue, Apr 28$-0.99 vs $-1.02beat
Estimates and results for ODT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ODThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsseekingalpha.com·2d ago·Positive
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst Definium Therapeutics remains a 'Strong Buy' following positive phase 3 VOYAGE data for DT120 ODT in generalized anxiety disorder [GAD]. The company's DT120 ODT achieved a statistically significant -5.4 placebo-adjusted reduction in HAM-A score at 12 weeks in GAD, highlighting best-in-class potential. Upcoming catalysts include phase 3 PANORAMA GAD data in September 2026 and ASCEND MDD to
View source ↗